We previously provided repeated thermal therapy using an infrared-ray dry sauna evenly maintained at 60°C for patients with chronic heart failure and reported that it improved the hemodynamics and symptoms.\(^1\)\(^-\)\(^4\) Furthermore, we previously showed in vivo that the advantageous effect is based in part on the up-regulation of the endothelial nitric oxide synthase (eNOS) expression level after repeated thermal therapy.\(^5\)\(^6\) In this report, we describe a patient who suffered from Sjögren syndrome with complications of idiopathic dilated cardiomyopathy (DCM), and we demonstrate that repeated therapy using an infrared-ray dry sauna remarkably improved the symptoms of Sjögren syndrome as well as DCM. In addition, we simultaneously observed that this therapy down-regulated the abnormally high level of human leukocyte antigen (HLA)-A, B, C (major histocompatibility complex class I) expression on the monocytes to close to the normal range, regardless of the fact that the medications were left unchanged during the sauna therapy.

A 62-year-old female had been experiencing arthritic pain and dry mouth since April 2001; she was diagnosed to have Sjögren syndrome and had been taking the appropriate medication. Subsequently, she developed the subjective symptom of shortness of breath on effort in 2002, was diagnosed with DCM, and medical follow-up treatment was initiated. She was admitted to our hospital in March 2004. On admission, xerostomia, xerophthalmia and arthritis from Sjögren syndrome were particularly noticeable. The severity of cardiac failure was New York Heart Association (NYHA) class II–III, and the white blood count, C-reactive protein and brain natriuretic peptide (BNP) levels were 4,900 /µl, 1.05 mg/dl and 118 pg/ml, respectively. Other notable findings were that the anti-RNP antibody and anti-Sm antibody were positive, and the anti-DNA antibody was 3 IU/ml. The anti-SSA and anti-SSB antibodies were negative. Ultrasonic cardiography showed the left ventricular diastolic volume (LVDV), left ventricular systolic volume (LVSV) and ejection fraction (EF) were 150 ml, 111 ml and 26%, respectively.

After 20 times of repeated thermal therapy once each day for 4 weeks, cardiac dysfunction improved (LVDV = 106 ml, LVSV = 67 ml, EF = 37%, BNP = 40 pg/ml, NYHA class I–II). In addition, the subjective symptoms of Sjögren syn-
Sjögren syndrome, in particular, xerostomia and arthritis, were all dramatically alleviated (Figs. 1–A, B). On the other hand, we examined the HLA-A, B, C expression level on the circulating monocytes, which activated the CD8+ cytotoxic T lymphocytes\(^7,8\) and are capable of inhibiting the cytotoxic activity of the NK cells,\(^9\) by flow-cytometry before and after the 20 sessions of repeated thermal therapy. The results showed that she had an HLA-A, B, C expression level which was 3.4 times higher than the mean value of the normal volunteers \((n = 23)\) before the thermal therapy, but after the thermal therapy, the level was down-regulated and even approached the normal range \((\text{mean} \pm 2\text{SD}, n = 23);\)

Figs. 1–C, D. We hypothesized that this modulation of HLA-A, B, C on the monocytes may thus be associated with the alleviation of the symptoms of Sjögren syndrome, and our study investigating this mechanism is now currently in progress.

This case shows that thermal therapy may qualify as a treatment for Sjögren syndrome. Furthermore, repeated thermal therapy was found to effectively alleviate the symptoms of three consecutive patients with Sjögren syndrome, in particular the symptoms of xerostomia and arthritis, without any complications.
References


